Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) announced it will report its second quarter financial results on August 10, 2020. The company will not hold a traditional business update call but plans a conference call in September to share top-line results from its PRO2TECT Phase 3 cardiovascular outcomes studies. These studies involved 3,513 patients and investigated the efficacy of vadadustat for treating anemia due to chronic kidney disease (CKD). The PRO2TECT database has been locked, marking a key milestone in the development of vadadustat.
Akebia Therapeutics (Nasdaq: AKBA) announced a new investigator-sponsored study to evaluate vadadustat as a potential therapy for acute respiratory distress syndrome (ARDS) in COVID-19 patients. Conducted by UTHealth in Houston, the randomized, placebo-controlled trial aims to enroll up to 300 patients hospitalized for hypoxemia due to COVID-19. The dosing will start within 24 hours of admission and continue for up to 14 days. Vadadustat is also in Phase 3 trials for treating anemia due to chronic kidney disease and is currently approved for that use in Japan.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced on July 2, 2020, the grant of stock options to six newly-hired employees totaling 320,000 shares, including 280,000 shares for David Spellman, the new CFO. These options were granted as inducements for employment and comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.58 per share, reflecting the stock's closing price on the grant date, and will vest over four years.
Akebia Therapeutics has received regulatory approval for vadadustat, an oral therapy for anemia due to chronic kidney disease (CKD), from Japan's Ministry of Health, Labour and Welfare. This milestone allows Akebia's partner, Mitsubishi Tanabe Pharma Corporation (MTPC), to market vadadustat under the name VAFSEO in Japan. The approval follows a successful application filed in July 2019 and enables a $15 million milestone payment to Akebia. Akebia could further earn up to $190 million in additional payments and royalty rates up to 20% on sales in Japan and other Asian countries.
Akebia Therapeutics (Nasdaq: AKBA) has appointed David A. Spellman as the new Senior Vice President, Chief Financial Officer, and Treasurer, effective June 29, 2020. Spellman brings over 20 years of financial experience from companies like Intarcia and Vertex Pharmaceuticals. His role will be crucial as Akebia advances vadadustat, an investigational therapy in Phase 3 for treating anemia due to chronic kidney disease (CKD). Former CFO Jason A. Amello transitions out after 7 years to pursue other interests, ensuring a smooth handover during the transition.